CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting
The company confirms its sales target of €10-13 million for 2023 Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world's most advanced total artificial heart